AGAP2 and gastric cancer: The GC patients were divided into groups with high (n = 25, fold change ≥ median) and low AGAP2-AS1 expression (n = 25, fold change ≤ median) to investigate the relationship between this variable and clinicopathology in such patients (Fig. 1d).